“I am in a place I never knew existed. This is a place that I dreamed about.”
That’s Tandem’s Molly McElwee-Malloy and the “place” she dreamed about is using the newest automated pump/CGM system. Tandem’s Control-IQ was approved by the FDA on December 13, 2019 but, as she told me in this week’s podcast, she’s already been wearing it as part of clinical trials.
“I’m not worried about what’s happening with my blood sugar,” she says. “We had my daughter’s third birthday this past weekend, and I didn’t worry about whether I bolused enough for the cupcake because it had my back. I didn’t worry the whole day and I stayed in range the whole day”
Molly’s speaking for herself there, not making any company claims. But she goes into detail about what the software can officially do (and what it can’t) in this week’s episode.
I’ve talked to Molly before over the years and she’s the perfect person to speak about Control IQ. She quit her job as a musician in 2006 after taking part in an early clinical trial. That one involved IVs and laptop computers and a hospital stay. But once she tasted that “freedom” from diabetes, she knew she needed more. She became a nurse and a CDE and went to work for Type Zero, the software that’s now used as part of Control IQ.
Now, as Clinical Outcomes Manger with Behavioral Sciences for Tandem, Molly told me, “t’s been a very long journey, a very difficult journey, but to be here today, wearing the device is magical.”
Find out more. Listen to this week’s episode right here:
Get more info and read the transcript at the episode home page: